Enterprise Value
-26.77M
Cash
150.3M
Avg Qtr Burn
-22.86M
Short % of Float
13.26%
Insider Ownership
0.95%
Institutional Own.
72.57%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMS-986288 (Anti-CTLA-4 non-fucosylated Probody) Details Colorectal cancer , Solid tumor/s | Phase 2 Data readout | |
CX-801 Details Cancer, Solid tumor/s, Melanoma, Renal cell carcinoma, Head and neck squamous cell carcinoma | Phase 1a Data readout | |
CX-2051 (EpCAM expression) Details Cancer, Solid tumor/s | Phase 1a Data readout | |
CX-904 (EGFRxCD3) Details Cancer, Solid tumor/s | Phase 1a Data readout | |
Pacmilimab (CX-072) + CX-2009 (PD-L1 Targeting Probody Immunotherapy + CD166 PDC) Details Cancer, Triple-negative breast cancer | Failed Discontinued | |
BMS-986249 (CTLA-4-directed Probody therapeutic) Details Cancer, Melanoma | Failed Discontinued | |
CX-2029 (PDC directed against CD71) Details Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s | Failed Discontinued | |
Praluzatamab ravtansine (CX-2009) (anti-CD166) Details Cancer, HER2-expressing cancers, Breast cancer | Failed Discontinued |